Fig. 5.
Dose-response curves for CDC.
Lymphoma cells (FL4 in upper panel, FL3 in lower panel) were incubated for 2 hours with graded doses of rituximab (horizontal axis) in the presence of increasing amounts of human serum (2%, 10%, 30%, and 50%), either heat-decomplemented (DEC) or native (non-DEC). Cell viability was determined by PI exclusion and is represented on the vertical axis.